Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

NanoCarrier Co., Ltd. (3NQ) AI Stock Analysis

0 Followers
DE:3NQ

NanoCarrier Co., Ltd.

(Frankfurt:3NQ)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue reboundThe sharp 2026 revenue rebound indicates that demand and commercial activity can recover after prior declines. If this improvement persists, a larger revenue base could provide operating leverage, support continued development of the DDS platform, and improve the company’s ability to fund future growth.
Negative Factors
Persistent unprofitabilityPersistent and very deep losses show that the business model has not yet reached sustainable profitability despite the recent revenue recovery. Continued losses can consume equity, restrict strategic flexibility, and make future progress dependent on successful commercialization or additional funding.

NanoCarrier Co., Ltd. (3NQ) vs. iShares MSCI Germany ETF (EWG)

-60%-40%-20%0%20%40%DE:3NQ-48.49%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 36.20M
Dividend Yield
―
Average Volume (3M)
8,040
Price to Earnings (P/E)
-5.0
Beta (1Y)
0.70
Revenue Growth
34.57%
EPS Growth
-32.41%
Country
Germany
Employees
23
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

NanoCarrier Co., Ltd. Business Overview & Revenue Model

Company Description

Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 P...

NanoCarrier Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:3NQ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4588JP:458851NeutralJPY 226.57B-152.49――1748.97%35.11%
JP:4583JP:458347NeutralJPY 6.22B-6.19――-13.40%7.50%
JP:4563JP:456342NeutralJPY 10.72B-2.83-163.39%―19.67%84.06%
JP:4564JP:456441NeutralJPY 6.94B-6.96-42.81%―-25.56%17.01%
JP:4888JP:488833UnderperformJPY 13.62B-14.26――-67.40%-524.23%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%DE:3NQJP:4563JP:4564JP:4583JP:4588JP:4888Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:3NQ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:3NQNanoCarrier Co., Ltd.0.38-0.36-48.84%
JP:4563AnGes 27.00-48.00-64.00%
JP:4564OncoTherapy Science, Inc.16.00-7.00-30.43%
JP:4583Chiome Bioscience Inc.77.00-46.00-37.40%
JP:4588Oncolys BioPharma, Inc.8410.007342.00687.45%
JP:4888STELLA PHARMA CORPORATION355.00111.0045.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.